Drug monotherapy in patients with uterine myoma

Objective. To evaluate the efficiency of using gynestril (mifepristone, 50 mg) in the medical treatment of patients with uterine myoma. Subject and methods. Seventy-three women aged 25 to 40 years who were seeking organ-sparing treatment for uterine myoma as they planned childbirth in the future were followed up. During their primary examination and follow-up, all the patients underwent comprehensive studies involving evaluation of general health status, gynecological examination, small pelvic and breast ultrasonography, office hysteroscopy and histological examination of pipelle endometrial biopsy specimens. Results. The authors present their data on the prevalence of uterine myoma in women from different age groups, as well in those with infertility, miscarriage, and other internal genital diseases. There are data on the detection rate of concomitant somatic and gynecological diseases in patients with uterine myoma. There is also evidence for the use of mifepristone (50 mg) for the medical therapy of women with uterine myoma. Conclusion. The antigestagenic monotherapy caused the most pronounced reduction in myomatous nodules of baseline small sizes.

uterine myoma, prevalence, concomitant somatic and gynecological diseases, treatment, mifepristone (50 mg)